RSRoxine Staats

Roxine Staats

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roxine Staats has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global kinetic model of lipid-induced α -synuclein aggregation and its inhibition by small molecules

    by Alisdair Stevenson, Roxine Staats, Alexander J. Dear, David Voderholzer, Georg Meisl, Raphael Guido, Céline Galvagnion, Alexander K. Buell, Tuomas P. J. Knowles, Michele Vendruscolo, et al.

    The aggregation of α -synuclein into amyloid fibrils is a hallmark of Parkinson’s disease. This process has been shown to directly involve interactions between proteins and lipid surfaces when the latter are present. Despite this importance, the molecular mechanisms of lipid-induced amyloid aggregation have remained largely elusive. Here, we present a global kinetic model to describe lipid-induced amyloid aggregation of α -synuclein. Using this framework we find that α -synuclein fibrils form via a two-step primary nucleation mechanism and that lipid molecules are directly involved in both the nucleation and fibril elongation steps, giving rise to lipid-protein coaggregates. To illustrate the applicability of this kinetic approach to drug discovery, we identify the mechanism of action of squalamine, a known inhibitor of α-synuclein aggregation, finding that this small molecule reduces the rate of lipid-dependent primary nucleation. Our work will likely guide the rational design of α -synuclein aggregation inhibitors. Significance Statement: Amyloid aggregation is a hallmark of a diverse range of diseases including Parkinson’s Disease, where the protein α -synuclein is a major con-stituent of proteinaceous deposits found in patients. It is well established that interactions between α -synuclein and lipids modulate aggregation. However, the molecular mechanisms driving this lipid-induced aggregation have remained largely elusive, which has frustrated so far the discovery of drugs that prevent lipid-induced aggregation. In this work, we present the first global kinetic model describing lipid-induced aggregation and by integrating this theoretical framework with in vitro experimental data of lipid-induced α -synuclein aggregation, we reveal the role of lipid membranes in the aggregation process and uncover the mechanism by which small molecule inhibitors interfere with this process.


  • Open Access

    A Machine Learning Approach to Identify Small Molecule Inhibitors of Secondary Nucleation in α-Synuclein Aggregation

    by Robert Horne, Andrea Possenti, Sean Chia, Z. Faidon Brotzakis, Roxine Staats, Magdalena Nowinska, Michele Vendruscolo

    Drug development is an increasingly active area of application of machine learning, prompted by the need to overcome the high attrition rates of conventional drug discovery pipelines. This issue is especially pressing for neurodegenerative diseases, where disease-modifying drugs are not widely available yet. To address this problem, we describe an approach based on a combination of machine learning with chemical kinetics to target diseases caused by protein misfolding and aggregation. We use this approach to identify specific inhibitors of the proliferation of α-synuclein aggregates through secondary nucleation, a process implicated in Parkinson’s disease. Our results demonstrate that this approach leads to the identification of novel chemical matter with an improved hit rate and potency over more traditional approaches.

  • Open Access

    Screening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter

    by Roxine Staats, Thomas C. T. Michaels, Patrick Flagmeier, Sean Chia, Robert I. Horne, Johnny Habchi, Sara Linse, Tuomas P. J. Knowles, Christopher M. Dobson, Michele Vendruscolo

    The aggregation of α-synuclein is a central event in Parkinsons’s disease and related synucleinopathies. Since pharmacologically targeting this process, however, has not yet resulted in approved disease-modifying treatments, there is an unmet need of developing novel methods of drug discovery. In this context, the use of chemical kinetics has recently enabled accurate quantifications of the microscopic steps leading to the proliferation of protein misfolded oligomers. As these species are highly neurotoxic, effective therapeutic strategies may be aimed at reducing their numbers. Here, we exploit this quantitative approach to develop a screening strategy that uses the reactive flux toward α-synuclein oligomers as a selection parameter. Using this approach, we evaluate the efficacy of a library of flavone derivatives, identifying apigenin as a compound that simultaneously delays and reduces the formation of α-synuclein oligomers. These results demonstrate a compound selection strategy based on the inhibition of the formation of α-synuclein oligomers, which may be key in identifying small molecules in drug discovery pipelines for diseases associated with α-synuclein aggregation.